Theravance Outlines $250M Capital Return Program; To Repurchase GSK's Entire Holdings

  • Theravance Biopharma Inc TBPH is buying back over 9.6 million shares from GSK plc GSK for roughly $94 million, according to an SEC filing
  • In addition, Theravance plans to buy back $95 million from its existing investors "in the near term" and another $60 million in its shares on the open market. 
  • In a press release, Theravance says it hopes to complete that part of its plan by the end of 2023.
  • Related content: Theravance Biopharma's Ampreloxetine Shows Benefit In Atrophy Patients, But Not In Parkinson's.
  • The move is the latest in a back-and-forth between GSK, Theravance, and Theravance's spinoff Innoviva, Inc. INVA.
  • In May 2021, GSK offloaded its stake in Innoviva with 32 million shares at $12.25 per share, raising gross proceeds of approximately $392 million.
  • In July, Theravance and Innoviva sold their royalty rights to GSK's Trelegy to Royalty Pharma RPRX for an upfront $1.3 billion.
  • Price Action: TBPH shares are up 2.48% at $10.32 on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareBuybacksSmall CapGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!